Pharmaceutical Sustainability Initiatives

1131 Words3 Pages

Pharmaceutical company as an industry has been accepted as the leader of sustainability measures Due to their exclusive position as health suppliers, any efforts taken for sustainability is considered to be the building block to achieve their vision, mission and long term goals.

Initially the incorporation of sustainability initiatives with the profit maximisation motive of the company was based on the following factors:
• Incorporation of the sustainability measures in the VMO of the company.
• Extended support from the higher authorities towards these measures.
• Involving all stakeholders to become a part of the initiative and take them into consideration on all sustainable activities.
• Observing, evaluating and process focus improvement. …show more content…

Companies like Astra Zeneca are trying to help those who are uninsured and underinsured to get easy access to medicines.

Different companies have different form of sustainable activities and it differs from one sector to another, there is no distinctive footprint of participation in the standards. A majority of pharmaceutical companies invest in sustainability reporting which helps them in managing their sustainable activities and benchmarking. This is extremely useful to the participants even while remaining a process focus. With the advent of CSR in the pharmaceutical companies, there would be comprehensive reporting on the impact on society.

As CSR emerges, perhaps the pharmaceuticals will truly begin to prepare comprehensive reports and measure their impact on society and the earth. The companies are using its CSR activities as a tool to enhance its corporate brand value and reputation. This shift not only provides a platform to display effort that reacts to societal expectations and takes initiatives that is most fruitful for the …show more content…

This will help them reduce the time taken for drug development as they can simultaneously focus on integration of external resources with internal activities and create a synergy between the two. Core activities also involve huge capital expense. Thus, by shifting their focus and strategically outsourcing these activities, a sustainable competitive advantage can be created that concentrates on improving drug substance process development technologies that will bring down the time and cost involved in drug molecule synthesis.

However, there is a perception problem in the pharmaceutical industry that needs to be addressed. Organisations feel that the work done on core activities should be in-house and that outsourcing them will only affect the quality of work. This myth needs to be dispelled. Also, such strategic restructuring requires a fundamental change in the way the organisation works and employees are handled. This is by no means a small feat and requires the top management to truly believe that such structural changes are going to be very beneficial to the

Open Document